European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock — Oct 18th, 2024

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock...

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout — Oct 21st, 2024

(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. Maselli's open letter comes on the back of criticism...

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings — Oct 21st, 2024

Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabl...

Consumer groups ask FTC to block Novo Holdings-Catalent deal — Oct 17th, 2024

By Jody Godoy and Maggie Fick NEW YORK (Reuters) -U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk, from acquiring contract drug manufacturer Catalent, saying the deal th...

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings — Oct 21st, 2024

Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabl...

Catalent Stock Flat Following the Sell Agreement With Ardena — Oct 16th, 2024

Catalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ, to Ardena. Ardena is a Contract Development and Manufacturing Organization with locations in Belgium, Spain, the Neth...

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout — Oct 21st, 2024

(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. Maselli's open letter comes on the back of criticism...

Consumer groups ask FTC to block Novo Holdings-Catalent deal — Oct 17th, 2024

By Jody Godoy and Maggie Fick NEW YORK (Reuters) -U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk, from acquiring contract drug manufacturer Catalent, saying the deal th...

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout — Oct 21st, 2024

(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. Maselli's open letter comes on the back of criticism...

Catalent Stock Flat Following the Sell Agreement With Ardena — Oct 16th, 2024

Catalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ, to Ardena. Ardena is a Contract Development and Manufacturing Organization with locations in Belgium, Spain, the Neth...

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock — Oct 18th, 2024

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock...

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout — Oct 21st, 2024

(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. Maselli's open letter comes on the back of criticism...

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout — Oct 21st, 2024

(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. Maselli's open letter comes on the back of criticism...

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings — Oct 21st, 2024

Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabl...

Consumer groups ask FTC to block Novo Holdings-Catalent deal — Oct 17th, 2024

By Jody Godoy and Maggie Fick NEW YORK (Reuters) -U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk, from acquiring contract drug manufacturer Catalent, saying the deal th...

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings — Oct 21st, 2024

Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabl...

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout — Oct 21st, 2024

(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. Maselli's open letter comes on the back of criticism...

Consumer groups ask FTC to block Novo Holdings-Catalent deal — Oct 17th, 2024

By Jody Godoy and Maggie Fick NEW YORK (Reuters) -U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk, from acquiring contract drug manufacturer Catalent, saying the deal th...

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock — Oct 18th, 2024

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock...

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock — Oct 18th, 2024

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock...

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout — Oct 21st, 2024

(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. Maselli's open letter comes on the back of criticism...

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout — Oct 21st, 2024

(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. Maselli's open letter comes on the back of criticism...

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings — Oct 21st, 2024

Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabl...

Catalent Stock Flat Following the Sell Agreement With Ardena — Oct 16th, 2024

Catalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ, to Ardena. Ardena is a Contract Development and Manufacturing Organization with locations in Belgium, Spain, the Neth...

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings — Oct 21st, 2024

Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabl...

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout — Oct 21st, 2024

(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. Maselli's open letter comes on the back of criticism...

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings — Oct 21st, 2024

Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabl...

Consumer groups ask FTC to block Novo Holdings-Catalent deal — Oct 17th, 2024

By Jody Godoy and Maggie Fick NEW YORK (Reuters) -U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk, from acquiring contract drug manufacturer Catalent, saying the deal th...

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout — Oct 21st, 2024

(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. Maselli's open letter comes on the back of criticism...

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings — Oct 21st, 2024

Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabl...

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock — Oct 18th, 2024

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock...

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock — Oct 18th, 2024

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock...

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock — Oct 18th, 2024

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock...

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock — Oct 18th, 2024

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock...

Catalent Stock Flat Following the Sell Agreement With Ardena — Oct 16th, 2024

Catalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ, to Ardena. Ardena is a Contract Development and Manufacturing Organization with locations in Belgium, Spain, the Neth...

Consumer groups ask FTC to block Novo Holdings-Catalent deal — Oct 17th, 2024

By Jody Godoy and Maggie Fick NEW YORK (Reuters) -U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk, from acquiring contract drug manufacturer Catalent, saying the deal th...

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings — Oct 21st, 2024

Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabl...

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout — Oct 21st, 2024

(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. Maselli's open letter comes on the back of criticism...

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings — Oct 21st, 2024

Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabl...

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock — Oct 18th, 2024

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock...

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout — Oct 21st, 2024

(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. Maselli's open letter comes on the back of criticism...

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings — Oct 21st, 2024

Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabl...

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings — Oct 21st, 2024

Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabl...

Consumer groups ask FTC to block Novo Holdings-Catalent deal — Oct 17th, 2024

By Jody Godoy and Maggie Fick NEW YORK (Reuters) -U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk, from acquiring contract drug manufacturer Catalent, saying the deal th...

Consumer groups ask FTC to block Novo Holdings-Catalent deal — Oct 17th, 2024

By Jody Godoy and Maggie Fick NEW YORK (Reuters) -U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk, from acquiring contract drug manufacturer Catalent, saying the deal th...

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings' buyout — Oct 21st, 2024

(Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will stay on as the contract drugmaker's chief after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. Maselli's open letter comes on the back of criticism...

Catalent Stock Flat Following the Sell Agreement With Ardena — Oct 16th, 2024

Catalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ, to Ardena. Ardena is a Contract Development and Manufacturing Organization with locations in Belgium, Spain, the Neth...

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings — Oct 21st, 2024

Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabl...

Consumer groups ask FTC to block Novo Holdings-Catalent deal — Oct 17th, 2024

By Jody Godoy and Maggie Fick NEW YORK (Reuters) -U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk, from acquiring contract drug manufacturer Catalent, saying the deal th...

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock — Oct 18th, 2024

European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock...